Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

Rizvi Hira; Sanchez-Vega Francisco; La Konnor; Chatila Walid; Jonsson Philip; Halpenny Darragh; Plodkowski Andrew; Long Niamh; Sauter Jennifer L.; Rekhtman Natasha; Hollmann Travis; Schalper Kurt A.; Gainor Justin F.; Shen Ronglai; Ni Ai; Arbour Kathryn C.; Merghoub Taha; Wolchok Jedd; Snyder Alexandra; Chaft Jamie E.; Kris Mark G.; Rudin Charles M.; Socci Nicholas D.; Berger Michael F.; Taylor Barry S.; Zehir Ahmet; Solit David B.; Arcila Mina E.; Ladanyi Marc; Riely Gregory J.; Schultz Nikolous; Hellmann Matthew D.

首页> 外文期刊>Journal of Clinical Oncology >Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

【24h】

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

机译：对具有靶向下一代测序的非小细胞肺癌患者患者反应对抗编程细胞死亡（PD）-1和抗程序死亡 - 配体1（PD-L1）阻断的分子决定因素

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2018年第7期|共35页
作者
Rizvi Hira; Sanchez-Vega Francisco; La Konnor; Chatila Walid; Jonsson Philip; Halpenny Darragh; Plodkowski Andrew; Long Niamh; Sauter Jennifer L.; Rekhtman Natasha; Hollmann Travis; Schalper Kurt A.; Gainor Justin F.; Shen Ronglai; Ni Ai; Arbour Kathryn C.; Merghoub Taha; Wolchok Jedd; Snyder Alexandra; Chaft Jamie E.; Kris Mark G.; Rudin Charles M.; Socci Nicholas D.; Berger Michael F.; Taylor Barry S.; Zehir Ahmet; Solit David B.; Arcila Mina E.; Ladanyi Marc; Riely Gregory J.; Schultz Nikolous; Hellmann Matthew D.;
展开▼
作者单位

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Yale Sch Med New Haven CT USA;

Massachusetts Gen Hosp Boston MA 02114 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Weill Cornell Med Coll New York NY USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

Mem Sloan Kettering Canc Ctr 885 2nd Ave New York NY 10017 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing (vol 36, pg 633, 2018) [J] . Journal of Clinical Oncology . 2018,第16期

机译：对非小细胞肺癌的患者具有靶向下一代测序的非小细胞肺癌（Vol 36）的患者响应反编程细胞死亡（Pd）-1和抗程序死亡 - 配体1（PD-L1）阻断的分子决定因素 PG 633,2018）
2. Molecular Determinants of Response to AntieProgrammed Cell Death (PD)-1 and AntieProgrammed Death-Ligand (PD-L)-Ligand 1 Blockade in Patients with NSCLC Profiled with Targeted Next-Generation Sequencing [J] . Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2018,第4期

机译：患有针对NSCLC的NSCLC患者的抗预编程细胞死亡（Pd）-1和抗预编程死亡配体（PD-1）-ligand的分子决定因素及其靶向下一代测序的患者
3. Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non-Small-Cell Lung Cancer Results of a 2-Year Experience on 1343 Samples [J] . Legras Antoine, Barritault Marc, Tallet Anne, The Journal of molecular diagnostics: JMD . 2018,第4期

机译：常规护理中靶向下一代测序的有效性，用于在1343个样品上鉴定非小细胞肺癌中的临床相关分子型材的临床相关分子曲线
4. Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma [C] . Yeul Hong Kim, Hye Sook Kim, Jae Sook Sung, Molecular Medicine TRI-CON. . 2014

机译：下一代测序对非小细胞肺癌抗蛋白酶激酶抑制剂进行下一代测序检测的低负荷EGFR突变的预测疗效
5. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. [D] . 野﨑, 結 2019

机译：PD-L1特异性辅助性T细胞表现出有效的抗肿瘤反应：针对头颈部鳞状细胞癌中PD-L1的癌症免疫疗法的新策略。
6. Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing [O] . Hira Rizvi, Francisco Sanchez-Vega, Konnor La, -1

机译：靶向靶向下一代测序的非小细胞肺癌患者对抗程序性细胞死亡（PD）-1和抗程序性死亡配体1（PD-L1）阻断反应的分子决定因素
7. Silencing Signal Transducer and Activator of Transcription 3 (STAT3) and Use of Anti-Programmed Cell Death-Ligand 1 (PD-L1) Antibody Induces Immune Response and Anti-Tumor Activity [O] . Jiaxing Wang, Fakun Huang, Caiyun Jiang, 2020

机译：沉默信号传感器和转录激活剂3（STAT3）和使用抗程序化细胞死亡 - 配体1（PD-L1）抗体诱导免疫应答和抗肿瘤活性

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅